Trillium Asset Management LLC Has $497,000 Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Trillium Asset Management LLC reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 34.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,518 shares of the medical instruments supplier’s stock after selling 784 shares during the period. Trillium Asset Management LLC’s holdings in West Pharmaceutical Services were worth $497,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of WST. Whipplewood Advisors LLC acquired a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at about $25,000. Retirement Wealth Solutions LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth approximately $34,000. Centricity Wealth Management LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth approximately $35,000. Cornerstone Planning Group LLC grew its stake in shares of West Pharmaceutical Services by 57.1% during the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 40 shares in the last quarter. Finally, Brooklyn Investment Group bought a new stake in shares of West Pharmaceutical Services in the third quarter worth $41,000. Institutional investors own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

WST has been the subject of a number of analyst reports. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Evercore ISI began coverage on West Pharmaceutical Services in a research note on Tuesday. They set an “outperform” rating and a $275.00 price objective on the stock. UBS Group raised shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their target price for the company from $350.00 to $390.00 in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a research report on Friday, February 14th. Finally, KeyCorp lowered their price objective on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and an average target price of $332.50.

West Pharmaceutical Services Price Performance

Shares of WST opened at $230.14 on Thursday. The company’s 50-day moving average is $279.03 and its 200-day moving average is $301.60. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. The firm has a market capitalization of $16.64 billion, a PE ratio of 34.40, a PEG ratio of 6.74 and a beta of 1.09. West Pharmaceutical Services, Inc. has a fifty-two week low of $197.01 and a fifty-two week high of $400.88.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.07. The firm had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be given a $0.21 dividend. The ex-dividend date is Wednesday, April 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.37%. West Pharmaceutical Services’s dividend payout ratio is currently 12.56%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.